One year after launching AI Agency, EVERSANA joined Google Cloud and more than 80 life sciences organizations at Google’s New York headquarters to explore a question facing the industry: How do pharmaceutical companies move from AI experimentation to AI-powered execution at scale?
The Shift From AI Pilots to Scalable Commercialization
The answer was a common theme throughout the event: the conversation around AI has evolved. Organizations are no longer focused on isolated pilots. Instead, they are looking for practical, compliant, and scalable ways to apply AI across commercialization.
Leaders from EVERSANA, Google, Lundbeck and other organizations came together to discuss how AI is reshaping pharmaceutical commercialization. From technology innovators to commercialization partners and pharmaceutical organizations actively deploying AI, speakers explored how the industry is moving beyond experimentation and scaling AI across strategy, content, medical communications, market access and commercial operations.
The event came on the heels of EVERSANA’s announcement of the expansion of its AI-powered commercialization platform with new capabilities across medical affairs, market research and commercial operations. In the week before the event, EVERSANA and Lundbeck announced an expanded strategic partnership to advance AI-powered commercialization, broadening Lundbeck’s use of AI Agency and related commercialization capabilities to help accelerate strategy development, content creation, omnichannel engagement and commercial execution.
As EVERSANA CEO Mark Thierer shared during the event:
“The pharmaceutical industry has reached an inflection point. Organizations are moving beyond isolated AI pilots and looking for practical ways to scale AI across commercialization.”
Industry Reception: Measurable Impact in Life Sciences
The event and the evolution of AI Agency generated significant industry attention, including coverage from MM+M, PM360, and Med Ad News.
MM+M Editor-at-Large Steve Madden highlighted the momentum behind AI Agency, writing:
“EVERSANA’s AI Agency is a pretty much tail to snout commercialization product that promises rapid gains in efficiencies, among other benefits. Clients are enthusiastically embracing the new technology. EVERSANA’s competitors need to take note.”
While each publication covered the event from a different perspective, all pointed to the same conclusion: AI in life sciences is entering a new phase focused on adoption, scalability, and measurable impact.
Read the Latest AI Agency Media Coverage
- Med Ad News: EVERSANA Hosts 80 Companies with Google Cloud to Showcase What’s Next in AI Agency Commercialization
One year into AI Agency, the industry message is becoming increasingly clear: the question is no longer whether AI belongs in commercialization. It’s how organizations can responsibly scale it to create meaningful impact.
As one Google executive put it:
“There’s no going back.”
Read more about EVERSANA’s AI Agency platform
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…